Biomarkers, ketone bodies, and the prevention of Alzheimer's disease

Metabolism: Clinical and Experimental

Volumn 64, Issue 3, 2015, Pages S51-S57

  Vanitallie, Theodore B ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Amyloid cascade hypothesis; Endophenotype; Ketone ester; Magnetic resonance spectroscopy; Mitochondrial cascade hypothesis

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; BIOLOGICAL MARKER; KETONE BODY; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); GLUCOSE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; COMPARATIVE STUDY; DEMENTIA; DISEASE COURSE; HUMAN; KETOGENIC DIET; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SYNAPSE; AGE; ANIMAL; BLOOD; BRAIN; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TIME;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE; HUMANS; KETONE BODIES; MAGNETIC RESONANCE SPECTROSCOPY; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIA; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS;

EID: 84920988868     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.10.033     Document Type: Article

References (55)

1. Alzheimer's Association, 2014 Alzheimer's disease facts and figures. Alzheimer's Dement, Volume 10, Issue 2.
2. B. Croisile, S. Auricombe, F. Etcharry-Bouyx, M. Vercelletto, National Institute in Aging (US), and Alzheimer Association The new 2011 recommendations of the National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: preclinical stage, mild cognitive impairment and dementia Rev Neurol (Paris) 168 2012 471 482
3. C.R. Jack, D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen Update on hypothetical model of Alzheimer's disease biomarkers Lancet Neurol 12 2013 207 216
4. A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, and K. Iqbal Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments Proc Natl Acad Sci U S A 98 2001 6923 6928
5. A. Serrano-Pozo, M.P. Frosch, E. Masliah, and B.T. Hyman Neuropathological alterations in Alzheimer disease Cold Spring Harb Perspect Med 1 1 2011 a006189 10.1101/cshperspect.a006189
6. G.M. Cooper The cell, a molecular approach 2nd ed. 2000 Sinauer Associates Sunderland (MA)
7. P.W. Bass, and F.J. Ahmed Beyond taxol: microtubule-based treatment of disease and injury of the nervous system Brain 136 2013 2937 2951
8. L.C. Kapitein, K.W. Yau, and C.C. Hoogenraad Microtubules in dendritic spines Methods Cell Biol 97 2010 111 132
9. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, and R. Hill Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 30 1991 572 580
10. J. Asthana, S. Kapoor, R. Mohan, and D. Panda Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells J Biol Chem 288 2013 22516 22526
11. M. Medina, and J. Avila New perspectives on the role of tau in Alzheimer's disease. Implications for therapy Biochem Pharmacol 88 2014 540 547
12. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
13. B.V. Dickerson, and D.A. Wolk Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau Front Aging Neurosci 5 Article 55 2013 1 9
14. M. Mapstone, A.K. Cheema, M.S. Fiandaca, X. Zhong, T.R. Mhyre, and L.H. Macarthur Plasma phospholipids identify antecedent memory impairment in older adults Nat Med 2014 10.1038/nm.3466
15. S. Evans, N.G. Dowell, N. Tabet, P.S. Tofts, S.L. King, and J.M. Rusted Cognitive and neural signatures of the APOE E4 allele in mid-aged adults Neurobiol Aging 35 2014 1615 1623
16. S. Norton, F.E. Matthews, D.E. Barnes, K. Yaffe, and C. Brayne Potential for primary prevention of Alzheimer's disease: an analysis of population-based data Lancet Neurol 13 2014 788 794
17. L. Mosconi, J. Murray, W.H. Tsui, Y. Li, N. Spector, and A. Goldowsky Brain imaging of cognitively normal adults with 2 parents affected by late-onset AD Neurology 82 2014 752 760
18. J. Raber, Y. Huang, and J.W. Ashford ApoE genotype accounts for the vast majority of AD risk and AD pathology Neurobiol Aging 25 2004 641 650
19. A. Altmann, L. Tian, V.W. Henderson, and M.D. Greicius Sex modifies the APOE-related risk of developing Alzheimer disease Ann Neurol 75 2014 563 573
20. D.S. Knopman, C.R. Jack Jr., H.J. Wiste, E.S. Lundt, S.D. Weigand, and P. Vemuri 18 F-fluorodeoxyglucose positron emission tomography, aging, and apoliproprotein E genotype in cognitively normal persons Neurobiol Aging 2014 10.1016/j.neurobiolaging.2014.03.006 [pii: S0197-4580(14)00240-1, [Epub ahead of print]]
21. L.G. Apostolova, K.S. Hwang, O. Kohannim, D. Avila, D. Elashoff, and C.R. Jack Jr. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease Neuroimage Clin 4 2014 461 472
22. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer pathological cascade Lancet Neurol 9 2010 119 128
23. J. Hardy, and G. Higgins Alzheimer's disease: the amyloid cascade hypothesis Science 256 1992 184 185
24. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
25. D.M. Walsh, and D.J. Selkoe A beta oligomers - a decade of discovery J Neurochem 101 2007 1172 1184
26. R.H. Swerdlow, and S.M. Khan A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease Med Hypotheses 63 2004 8 20
27. R.H. Swerdlow, J.M. Burns, and S.M. Khan The Alzheimer's disease mitochondrial cascade hypothesis J Alzheimers Dis 20 2010 265 279
28. R.H. Swerdlow, J.M. Burns, and S.M. Khan The Alzheimer's disease mitochondrial casacade hypothesis: progress and perspectives Biochim Biophys Acta 2013 10.1016/j.bbadis.2013.09.010 [pii:So925-4439(13)00289-5, [Epub ahead of print]]
29. T.A. Bayer, and O. Wirths Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease Acta Neuropathol 127 2014 787 801
30. R.F. Lane, P.A. Dacks, D.W. Shineman, and H.F. Fillit Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's drug discovery foundation 2012 International Conference on Alzheimer's drug discovery Alzheimers Res Ther 5 2013 1 4
31. A. Goate, M.C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, and L. Fidani Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 349 1991 704 706
32. M.S. Wolfe Toward the structure of presenilin/γ-secretase and presenilin homologs Biochim Biophys Acta 2013 1828 2886 2897
33. R. Delabio, L. Rasmussen, I. Mizumoto, G.A. Viani, E. Chen, and J. Villares PSEN1 and PSEN2 gene expression in Alzheimer's disease brain: a new approach J Alzheimers Dis 2014 [Epub ahead of print]
34. M. Citron, D. Westaway, X. Weiming, G. Carlson, T. Diehl, and G. Levesque Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice Nat Med 3 1997 67 72
35. A. Boutajangout, and T. Wisniewski Tau-based therapeutic approaches for Alzheimer's disease - a mini-review Gerontology 60 2014 381 385
36. M.T. Lin, D.K. Simon, C.H. Ahn, L.M. Kim, and M.F. Beal High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain Hum Mol Genet 11 2002 133 145
37. P. Kumar, N.K. Jha, S.K. Jha, K. Ramani, and R.K. Ambasta Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease J Alzheimers Dis 2014 [Epub ahead of print]
38. C.W. Lee, Y.H. Shih, S.Y. Wu, T. Yang, C. Lin, and Y.M. Kuo Hypoglycemia induces tau phosphorylation Curr Alzheimer Res 10 2013 298 308
39. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, and O. Salvado Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
40. J.M. Ross, J.B. Stewart, E. Hagstom, S. Brene, A. Mourier, and G. Coppotelli Germline mitochondrial mutations aggravate aging and can impair brain development Nature 501 2013 412 415
41. E. Martinez, A. Navarro, C. Ordonez, E. Del Valle, and J. Tolivia Oxidative stress induces apolipoprotein D overexpression in hippocampus during aging and Alzheimer's disease J Alzheimers Dis 36 2013 129 144
42. L. Krukeja, G.C. Kujoth, T.A. Prolla, F. Van Leuven, and R. Vassar Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease Mol Neurodegener 9 2014 16 10.1186/1750-1326-9-16
43. S.M. de la Monte Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease Curr Alzheimer Res 9 2012 35 66
44. Z. Chen, and C. Zhong Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies Prog Neurobiol 108 2013 21 43
45. J. Yao, J.R. Rettberg, L.P. Klosinski, E. Cadenas, and Brinton R. Diaz Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions Mol Aspects Med 32 2011 247 257
46. K. Kantarci Magnetic resonance spectroscopy in common dementias Neuroimaging Clin N Am 23 2013 393 406
47. J.M. Ross, J. Oberg, S. Brene, G. Coppotelli, M. Terzioglu, and K. Pernold High brain lactate is a hallmark of aging and caused by a shift in the lactate dehydrogenase A/B ratio Proc Natl Acad Sci U S A 107 2010 20087 20092
48. S.A. Hashim, and T.B. VanItallie Ketone body therapy: from ketogenic diet to the oral administration of ketone ester J Lipid Res 55 2014 1818 1826
49. G. Blomqvist, M. Alvarsson, V. Grill, G. Von Heijne, M. Ingvar, and J.O. Thorell Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients Am J Physiol Endocrinol Metab 283 2002 E20 E28
50. Y. Kashiwaya, C. Bergman, J.H. Lee, R. Wan, M.T. King, and M.R. Mughal A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease Neurobiol Aging 34 2013 1530 1539
51. D.Y. Kim, J. Vallejo, and J.M. Rho Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors J Neurochem 114 2010 130 141
52. S.G. Jarrett, J.B. Milder, L.P. Liang, and M. Patel The ketogenic diet increases mitochondrial glutathione levels J Neurochem 106 2008 1044 1051
53. L. Massieu, M.L. Haces, T. Montiel, and K. Hernandez-Fonesca Acetoacetate protects hippocampal neurons against glutamate-mediated neuronal damage during glycolysis inhibition Neuroscience 120 2003 365 378
54. S.T. Henderson, J.L. Vogel, L. Barr, F. Garvin, J.J. Jones, and L.G. Costantini Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial Nutr Metab 6 2009 31 10.1186/1743-7075-6-31
55. M.T. Newport, T.B. VanItallie, Y. Kashiwaya, M.T. King, and R.L. Veech A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease Alzheimers Dement 2014 Oct 7 10.1016/j.jalz.2014.01.006 [Epub ahead of print]